ClinicalTrials.gg
TerminatedNCT06457997Updated Jan 29, 2026

A Study of PHN-010 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of PHN-010 in Lung Cancer, Colon Cancer and Endometrial Cancer, sponsored by Pheon Therapeutics. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Pheon Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated by Sponsor for strategic reasons.

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,460 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 643 under way, 52 of them phase 3. Lung Neoplasms · United States.

Enrollment
1,296th of 1,906
26 · median 48
Started
2024
with 105 others
Phase 1
447 of 2,460
57 open now
Registered
2,202nd of 2,460
by date

Among the 2,460 studies in Lung Neoplasms with a site in United States, this one is the 1,296th largest by enrollment of the 1,906 interventional ones that give a count, is one of 106 that started in 2024, is one of 447 in phase 1, and was the 2,202nd registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

422 of the 2,460 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

417 more — sign in →

All 422 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,460 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

03

Conditions studied

  • Lung Cancer
  • Colon Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Advanced Solid Tumor
  • Advanced Cancer

Keywords

  • Antibody-Drug Conjugate
  • Carcinoma
  • Cancer
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Has confirmed, advanced/:

    1. Colorectal adenocarcinoma (CRC), or
    2. Serous, endometroid, or clear-cell epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, or
    3. Serous, endometroid or clear-cell endometrial cancer, or
    4. Adenocarcinoma or squamous-cell carcinoma of the cervix, or
    5. Non-small cell lung cancer (NSCLC).
  • Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent , and for whom no further standard therapy is available or who is intolerant to standard therapy.
  • Has .
  • (ECOG) performance status of 0 or 1.
  • Has adequate organ function.
  • Has available tumor tissue sample at screening (either an collected ≤ 3 years prior to the date of or fresh biopsy material).

Exclusion Criteria:

  • Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.
  • Has unstable central nervous system metastasis.
  • Has persistent toxicities from previous systemic anti-cancer treatments of Grade >1.
  • Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.
  • Has received wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.
  • Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.
  • Has acute and/or bacterial, fungal, or viral infection including (HBV), (HCV), known (HIV).
  • Has a history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic , active NIP / ILD or suspected NIP / ILD which cannot be ruled out by imaging for Screening.

Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Phase 1a and Phase 1b

    PHN-010 is administered intravenously.

    Drug: PHN-010

Interventions

  • DrugPHN-010

    PHN-010 is an ADC

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (Phase 1a)

    Time frame: 18 months

  2. Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Phase 1a)

    Time frame: 18 months

  3. Frequency of dose interruptions, reductions, and discontinuations (Phase 1a and 1b)

    Time frame: 18 months

  4. Overall response rate (ORR) (Phase 1b)

    Time frame: 36 months

Secondary outcomes

  1. Best overall response (BOR) (Phase 1a and 1b)

    Time frame: 36 months

  2. Disease control rate (DCR) (Phase 1a and 1b)

    Time frame: 36 months

  3. Progression free survival (PFS) (Phase 1a and 1b)

    Time frame: 36 months

  4. Time to response (TTR) (Phase 1a and 1b)

    Time frame: 36 months

  5. Overall survival (OS) (Phase 1a and 1b)

    Time frame: 36 months

  6. Cancer antigen 125 (CA-125) response (Phase 1a and 1b)

    Time frame: 36 months

  7. Time to CA-125 response (Phase 1a and 1b)

    Time frame: 36 months

  8. Pharmacokinetics, maximum concentration (Cmax) of total ADC (Phase 1a and 1b)

    Time frame: 36 months

  9. Pharmacokinetics, Cmax of total antibody (Phase 1a and 1b)

    Time frame: 36 months

  10. Pharmacokinetics, Cmax of free payload (Phase 1a and 1b)

    Time frame: 36 months

  11. Pharmacokinetics, time of Cmax (Tmax) of total ADC (Phase 1a and 1b)

    Time frame: 36 months

  12. Pharmacokinetics, Tmax of total antibody (Phase 1a and 1b)

    Time frame: 36 months

  13. Pharmacokinetics, Tmax of free payload (Phase 1a and 1b)

    Time frame: 36 months

  14. Pharmacokinetics, area under the curve (AUC) of total ADC (Phase 1a and 1b)

    Time frame: 36 months

  15. Pharmacokinetics, AUC of total antibody (Phase 1a and 1b)

    Time frame: 36 months

  16. Pharmacokinetics, AUC of total free payload (Phase 1a and 1b)

    Time frame: 36 months

  17. Pharmacokinetics, terminal half-life (t1/2) of total ADC (Phase 1a and 1b)

    Time frame: 36 months

  18. Pharmacokinetics, t1/2 of total antibody (Phase 1a and 1b)

    Time frame: 36 months

  19. Pharmacokinetics, t1/2 of free payload (Phase 1a and 1b)

    Time frame: 36 months

  20. Concentration of anti-drug antibodies (Phase 1a and 1b)

    Time frame: 36 months

  21. Type, incidence and severity of AEs and SAEs (Phase 1b)

    Time frame: 18 months

07

Study locations

8 sites
  • AdventHealth
    Orlando, Florida 32804, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT - San Antonio
    San Antonio, Texas 78229, United States
  • NEXT - Virginia
    Fairfax, Virginia 22031, United States
  • University of Washington/Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Sep 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 13, 2024
StartActual
Jul 1, 2024
Primary completionActual
Sep 11, 2025
CompletionActual
Sep 11, 2025
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06457997
Lead sponsor
Pheon Therapeutics
Responsible party
Sponsor
First posted
Jun 13, 2024
Start date
Jul 1, 2024
Primary completion
Sep 11, 2025
Completion
Sep 11, 2025
Last update
Jan 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion